SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 13, 2012
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|3530 Toringdon Way, Suite 200, Charlotte, North Carolina||28277|
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code (704) 341-1516
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 8.01. Other Events.
On February 13, 2012, Chelsea Therapeutics International, Ltd. issued a press release announcing that its Chief Executive officer will review Chelseas New Drug Application to the U.S. Food and Drug Administration for NORTHERA (droxidopa) and provide an update on the upcoming FDA Advisory Committee meeting during the companys presentation at BIO CEO on February 13, 2012. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
|99.1||Press release dated February 13, 2012.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|CHELSEA THERAPEUTICS INTERNATIONAL, LTD.|
|Date: February 13, 2012|
|J. Nick Riehle, Chief Financial Officer|